Punjab Cancer Treatment Program Faces Severe Disruption
Thousands of blood cancer patients across Punjab are facing serious difficulties after a three-month disruption in the supply of free medicines under the provincial government Chronic Myeloid Leukemia treatment program. Around 5,000 patients are registered under the program, which provides four types of cancer medicines free of charge through five designated hospitals. These medical facilities serve individuals from various districts who rely completely on this public health initiative to manage their conditions. Patients normally collect their monthly supplies without direct cost, but administrative hurdles have halted the distribution channels.
The sudden halt in medication has placed an immense physical and financial burden on vulnerable citizens. Without regular access to prescribed therapies, individuals managing blood cancer disorders face worsening health outcomes. Medical professionals emphasize that continuity is vital in oncology care, making any prolonged break in treatment a dangerous scenario for patients who depend on public sector assistance. The disruption stems directly from administrative delays in government procurement and bidding procedures, leaving thousands waiting for a resolution.
Designated Hospitals and Affected Facilities
The treatment program operates through five designated hospitals located in major urban centers of the province. In Lahore, patients rely on Mayo Hospital and Jinnah Hospital for their monthly checkups and drug collection. In Multan, Nishtar Hospital serves as the primary hub for individuals residing in the southern districts. Benazir Bhutto Hospital handles cases in Rawalpindi, while Allied Hospital provides similar care for patients in Faisalabad. These institutions coordinate the distribution of specialized oncology drugs to registered individuals under the provincial health framework.
Patients travel from surrounding towns and rural areas to these specific locations, often spending considerable time and money on transport. When supplies run dry at these centers, the journey yields no results, forcing families to search elsewhere. The concentration of the program in only five hospitals means that any supply chain breakdown at the central level immediately affects the entire network of regional patients. Hospital administrators have had limited authority to resolve the issue until recently, compounding the difficulties faced by visitors.
Impact of Procurement Delays on Medicine Availability
Supplies have reportedly remained suspended for more than three months due to delays in the government procurement and bidding process. Public sector health departments must follow strict regulatory frameworks when acquiring pharmaceutical products on a large scale. These bureaucratic steps often involve inviting tenders, evaluating bids, and awarding contracts to suppliers who meet government standards. When administrative bottlenecks occur during these stages, the replenishment of hospital pharmacies stalls completely, creating severe inventory gaps.
The shortage has forced patients to purchase expensive medicines from private pharmacies, where the drugs are also reportedly in short supply. Commercial drug stores often lack specialized oncology products, or they price them far beyond the reach of average families. One of the affected drugs, Nilotinib, is a targeted therapy used to treat certain CML patients and often requires long-term treatment under specialist supervision. Procuring such specialized medication independently creates an unsustainable financial strain for households already dealing with chronic illness.
Health Risks of Treatment Interruptions
Medical experts have warned that prolonged treatment interruptions could pose serious health risks, particularly for patients who cannot afford the medicines. Chronic Myeloid Leukemia requires consistent management to keep cancer cells under control and prevent disease progression. When patients miss doses or stop therapy entirely, the cancer can become resistant to standard drugs or advance rapidly. Doctors stress that oncological treatments are not designed to be stopped abruptly, as restarting therapy later often proves more complicated and less effective.
The psychological toll on patients and their families matches the physical danger. Knowing that necessary drugs are unavailable creates severe anxiety among those who have built their lives around the monthly hospital visits. Many individuals have exhausted their personal savings and borrowed money from relatives to buy emergency supplies from private sellers. Without a swift return to free distribution, public health advocates fear that more patients will abandon their treatments out of sheer desperation.
Government Response and Steps Toward Resolution
Punjab Health Minister Khwaja Salman Rafique acknowledged the shortage and said the government was working to restore medicine supplies. He explained that leading oncologists had recommended expanding the number of prescribed cancer medicines under the program from four to 27 during consultations held about a year ago. Following the recommendation, the health department initiated a centralized procurement process for multiple medicines, while some drugs were already available in government stocks.
To address the immediate shortage, provincial health authorities have authorized the five designated hospitals to purchase medicines locally under the Local Purchase arrangement. The temporary measure is intended to ensure medicine availability while the centralized procurement process continues. Rafique expressed hope that the shortage would be resolved soon and patients would resume receiving free medicines at the designated hospitals. Hospital managements are currently reviewing local purchasing options to bring relief to the thousands of individuals waiting for their prescribed therapies.
